Show simple item record

dc.creatorHillner, Bruce E.en
dc.creatorSmith, Thomas J.en
dc.date.accessioned2015-05-05T18:39:11Zen
dc.date.available2015-05-05T18:39:11Zen
dc.date.created1991-01-17en
dc.date.issued1991-01-17en
dc.identifier10.1056/NEJM199101173240305en
dc.identifier.bibliographicCitationNew England Journal of Medicine. 1991 Jan 17; 324(3): 160-168.en
dc.identifier.issn0028-4793en
dc.identifier.urihttp://worldcatlibraries.org/registry/gateway?version=1.0&url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&atitle=Efficacy+and+Cost+Effectiveness+of+Adjuvant+Chemotherapy+in+Women+with+Node-Negative+Breast+Cancer:+a+Decision-Analysis+Model&title=New+England+Journal+of+Medicine.+&volume=324&issue=3&pages=160-168&date=1991&au=Hillner,+Bruce+E.en
dc.identifier.urihttp://dx.doi.org/10.1056/NEJM199101173240305en
dc.identifier.urihttp://hdl.handle.net/10822/737894en
dc.description.abstractThe purpose of this study was to explore the effectiveness of adjuvant therapy in node-negative breast cancer patients at different levels of risk of recurrence. Hillner and Smith created a model incorporating the variables of risk of recurrence, efficacy of adjuvant therapy, duration of benefit from therapy, and quality of life; and then used decision analysis to study the cost effectiveness of chemotherapy in cohorts of 45-year-old and 60-year-old women as adjusted for quality of life. They concluded from the data that chemotherapy substantially increases the quality-adjusted life expectancy of an average woman at a cost comparable to that of other widely acepted therapies. However, this benefit decreases markedly if the changes in long-term survival are less than in disease-free survival, rendering the benefit too small for many women to choose chemotherapy. This conclusion has policy implications for those who pay for cancer care. (KIE abstract)en
dc.formatArticleen
dc.languageenen
dc.sourceBRL:KIE/32278en
dc.subjectAge Factorsen
dc.subjectBreast Canceren
dc.subjectCanceren
dc.subjectCosts and Benefitsen
dc.subjectDecision Analysisen
dc.subjectDecision Makingen
dc.subjectDiseaseen
dc.subjectDrugsen
dc.subjectEconomicsen
dc.subjectEvaluationen
dc.subjectEvaluation Studiesen
dc.subjectFemalesen
dc.subjectHealthen
dc.subjectHealth Careen
dc.subjectLifeen
dc.subjectMortalityen
dc.subjectPatient Careen
dc.subjectPatient Participationen
dc.subjectPatientsen
dc.subjectPhysiciansen
dc.subjectPrognosisen
dc.subjectProlongation of Lifeen
dc.subjectQuality Adjusted Life Yearsen
dc.subjectQuality of Lifeen
dc.subjectResource Allocationen
dc.subjectRisken
dc.subjectRisks and Benefitsen
dc.subjectSelection for Treatmenten
dc.subjectToxicityen
dc.titleEfficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women With Node-Negative Breast Cancer: A Decision-Analysis Modelen
dc.provenanceDigital citation created by the National Reference Center for Bioethics Literature at Georgetown University for the BIOETHICSLINE database, part of the Kennedy Institute of Ethics' Bioethics Information Retrieval Project funded by the United States National Library of Medicine.en
dc.provenanceDigital citation migrated from OpenText LiveLink Discovery Server database named NBIO hosted by the Bioethics Research Library to the DSpace collection BioethicsLine hosted by Georgetown University.en


This item appears in the following Collection(s)

Show simple item record


Georgetown University Seal
©2009—2019 Bioethics Research Library
Box 571212 Washington DC 20057-1212
202.687.3885